{"id":420016,"date":"2021-01-25T07:33:10","date_gmt":"2021-01-25T12:33:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=420016"},"modified":"2021-01-25T07:33:10","modified_gmt":"2021-01-25T12:33:10","slug":"antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/","title":{"rendered":"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Study results expected to be presented in mid-2021<\/em>\n      <\/p>\n<p align=\"justify\">ATLANTA, Jan.  25, 2021  (GLOBE NEWSWIRE) &#8212; Antios Therapeutics, Inc. (\u201cAntios\u201d) today announced that it has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with chronic hepatitis B virus (HBV) infection. The Company expects to present the results of this study at an upcoming major medical conference in mid-2021.<\/p>\n<p align=\"justify\">\u201cDespite the availability of a vaccine, HBV remains a serious global public health problem with more than 250 million people worldwide living with chronic infection,\u201d said Gregory Mayes, chief executive officer of Antios. \u201cLife-long treatment with nucleoside analogues can control the infection by suppressing viral replication, but it rapidly rebounds in most patients when medication is stopped. ATI-2173\u2019s unique mechanism of action positions it as a promising clinical candidate and potential backbone treatment in a functional curative regimen for chronic HBV infection. We look forward to presenting the data to the scientific community at an upcoming medical conference.\u201d<\/p>\n<p align=\"justify\">The placebo-controlled Phase 1b trial evaluated the safety, tolerability, pharmacokinetics, and measurable reductions in HBV viral load of multiple oral doses of ATI-2173 in 24 patients with chronic HBV infection. The patients were randomized 6:2 to three dose cohorts: 10 mg, 25 mg or 50 mg of ATI-2173 or placebo, dosed orally, once-daily for 28 days. All doses were generally well tolerated with no apparent dose relationship for occurrence of adverse events, and no serious adverse events were observed. Based on the potent viral response observed, the 25 and 50 mg doses have been selected for the next clinical study that is expected to start in early 2021. More information on the trial can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jbf9pVDgF2UuZSvV3bHE5xWZA01YsaOUtnNI330HcKr5MGXPn_jAOBzRXJt81lvrDv4toSxDEHLXnkVffzNgfB5JaTUUk1RrGZRmHA4EfdbkKHLElIxumx81A4rCJNUfvHwxrU0wgFn7QoUOSusDwlOQgFHPdChQWMmIbW7G5cKSbiXtEe2cMja_kGxWRXAcNV8gEzLX5ijrPxz4vgtlWDpKi0qkIDkJEnjNdONUm-_s0FJKZYSGYGdoKVhTf9E-\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04248426?term=ATI-2173&amp;draw=2&amp;rank=1<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About ATI-2173<\/strong><br \/>\n        <br \/>ATI-2173 is a novel, orally-administered, liver-targeted Active Site Polymerase Inhibitor Nucleotide (ASPIN) molecule designed to deliver the 5\u2019-monophosphate of clevudine to the liver. This L-nucleoside\u2019s active 5\u2019-triphosphate has unique antiviral properties as a non-competitive, non-chain terminating HBV polymerase inhibitor that distorts the active site of HBV polymerase resulting in potent HBV antiviral activity and extended off-treatment suppression of HBV DNA. ATI-2173 targets the liver, delivering high levels of the unique 5\u2019- triphosphate while limiting systemic exposure to the parent L-nucleoside. ATI-2173 has the potential to become an integral part of a curative combination regimen for chronic hepatitis B.<\/p>\n<p align=\"justify\">\n        <strong>About Antios Therapeutics Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B infected patients with a curative combination regimen.<\/p>\n<p align=\"justify\">\n        <strong>CONTACTS:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Lee Roth<br \/>Burns McClellan<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HDgkCvNbpxvni7RyZmswyR19s3vn36hnBo5DBpPHFdPnM7GR0fe_vKmwyW45VuuZEHTE7xg14jnsmMvxwkt-og==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">lroth@burnsmc.com<\/a><br \/>+1 (212) 213-0006<\/p>\n<p align=\"justify\">\n        <strong>Media: <\/strong><br \/>\n        <br \/>Ryo Imai \/ Robert Flamm, Ph.D.<br \/>Burns McClellan<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-aeyOJLq07_y-VdBRYBQHfQytuMs1AnIcKm8EcD207WIL-j6QilbNnaWtlceryn0DovEm2bCYFlgioTebwmb8w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rimai@burnsmc.com<\/a> \/ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OoK4riNfPJVr8jSlnQ5TPD_Wr99nZCQN9opmUIcQzOKEg6SG_x5R6LdurGrJhP0EcSWgUKlDOEYQf6t9HtUxdJNRXHz6SI7HVUWObzVoWD0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rflamm@burnsmc.com<\/a><br \/>+1 (212) 300-8315 \/ +1 (212) 300-8364<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDE3NyMzOTQwMTA1IzIyMDU0ODA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ccfed54a-3ce0-4963-96df-e2a97faed198\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Study results expected to be presented in mid-2021 ATLANTA, Jan. 25, 2021 (GLOBE NEWSWIRE) &#8212; Antios Therapeutics, Inc. (\u201cAntios\u201d) today announced that it has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with chronic hepatitis B virus (HBV) infection. The Company expects to present the results of this study at an upcoming major medical conference in mid-2021. \u201cDespite the availability of a vaccine, HBV remains a serious global public health problem with more than 250 million people worldwide living with chronic infection,\u201d said Gregory Mayes, chief executive officer of Antios. \u201cLife-long treatment with nucleoside analogues can control the infection by suppressing viral replication, but it rapidly rebounds in most patients when &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-420016","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Study results expected to be presented in mid-2021 ATLANTA, Jan. 25, 2021 (GLOBE NEWSWIRE) &#8212; Antios Therapeutics, Inc. (\u201cAntios\u201d) today announced that it has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with chronic hepatitis B virus (HBV) infection. The Company expects to present the results of this study at an upcoming major medical conference in mid-2021. \u201cDespite the availability of a vaccine, HBV remains a serious global public health problem with more than 250 million people worldwide living with chronic infection,\u201d said Gregory Mayes, chief executive officer of Antios. \u201cLife-long treatment with nucleoside analogues can control the infection by suppressing viral replication, but it rapidly rebounds in most patients when &hellip; Continue reading &quot;Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-25T12:33:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDE3NyMzOTQwMTA1IzIyMDU0ODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection\",\"datePublished\":\"2021-01-25T12:33:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/\"},\"wordCount\":475,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDE3NyMzOTQwMTA1IzIyMDU0ODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/\",\"name\":\"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDE3NyMzOTQwMTA1IzIyMDU0ODA=\",\"datePublished\":\"2021-01-25T12:33:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDE3NyMzOTQwMTA1IzIyMDU0ODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDE3NyMzOTQwMTA1IzIyMDU0ODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/","og_locale":"en_US","og_type":"article","og_title":"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection - Market Newsdesk","og_description":"Study results expected to be presented in mid-2021 ATLANTA, Jan. 25, 2021 (GLOBE NEWSWIRE) &#8212; Antios Therapeutics, Inc. (\u201cAntios\u201d) today announced that it has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with chronic hepatitis B virus (HBV) infection. The Company expects to present the results of this study at an upcoming major medical conference in mid-2021. \u201cDespite the availability of a vaccine, HBV remains a serious global public health problem with more than 250 million people worldwide living with chronic infection,\u201d said Gregory Mayes, chief executive officer of Antios. \u201cLife-long treatment with nucleoside analogues can control the infection by suppressing viral replication, but it rapidly rebounds in most patients when &hellip; Continue reading \"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-25T12:33:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDE3NyMzOTQwMTA1IzIyMDU0ODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection","datePublished":"2021-01-25T12:33:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/"},"wordCount":475,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDE3NyMzOTQwMTA1IzIyMDU0ODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/","name":"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDE3NyMzOTQwMTA1IzIyMDU0ODA=","datePublished":"2021-01-25T12:33:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDE3NyMzOTQwMTA1IzIyMDU0ODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDE3NyMzOTQwMTA1IzIyMDU0ODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antios-therapeutics-completes-phase-1b-clinical-trial-of-ati-2173-an-active-site-polymerase-inhibitor-nucleotide-aspin-in-patients-with-chronic-hepatitis-b-virus-infection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/420016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=420016"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/420016\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=420016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=420016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=420016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}